Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus

Tim Hundscheid; Wes Onland; Elisabeth M.W. Kooi; Daniel C. Vijlbrief; Willem B. de Vries; Koen P. Dijkman; Anton H. van Kaam; Eduardo Villamor; André A. Kroon; Remco Visser; Susanne M. Mulder-de Tollenaer; Barbara De Bisschop; Peter H. Dijk; Daniela Avino; Catheline Hocq; Alexandra Zecic; Marisse Meeus; Tessa de Baat; Frank Derriks; Tine B. Henriksen; Kasper J. Kyng; Rogier Donders; Debbie H.G.M. Nuytemans; Bart Van Overmeire; Antonius L. Mulder; Willem P. de Boode

Journal ArticleOPEN ACCESS

Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus

Hundscheid T
Onland W
Kooi E
et al.

New England Journal of Medicine (2023) 388(11) 980-990

DOI: 10.1056/nejmoa2207418

172Citations

143Readers

Abstract

Abstract Background Cyclooxygenase inhibitors are commonly used in infants with patent ductus arteriosus (PDA), but the benefit of these drugs is uncertain. Methods In this multicenter, noninferior...

Cite

CITATION STYLE

APA

Hundscheid, T., Onland, W., Kooi, E. M. W., Vijlbrief, D. C., de Vries, W. B., Dijkman, K. P., … de Boode, W. P. (2023). Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus. New England Journal of Medicine, 388(11), 980–990. https://doi.org/10.1056/nejmoa2207418

Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus

Abstract

Cite

Register to see more suggestions